Myeloma UK news
A new survey being funded by Myeloma UK and carried out by the National Institute for Health and Care Excellence […]
Myeloma UK has launched a new type of Infoday designed exclusively to support the carers, family and friends of myeloma […]
Myeloma UK has launched a new Infopack to provide relapsed and/or refractory patients and their families with the information they […]
Myeloma UK is getting ready to attend the 2017 British Society of Haematology’s (BSH) Annual Scientific Meeting, which this year takes place in Brighton. Monica Morris is our Healthcare Professional Manager and is part of the Myeloma UK team attending the conference, “The BSH Annual Meeting attracts leading haematologists from across the UK to discuss the latest developments, not just in myeloma, but across a number of other haematological areas, and is a great opportunity for haematology doctors and nurses to learn about the latest developments in myeloma treatment and care.”
Myeloma UK has launched clinical trial MUK eleven which will open to recruitment imminently. It is a first of its kind immunotherapy trial which aims to encourage the immune system to target myeloma cells.
Myeloma UK is pleased to welcome Debbie Gardiner to our team of Myeloma Information Specialists. Debbie joins Ellen and Jude in providing information, support and practical advice to people affected by myeloma through our Myeloma Infoline and AskTheNurse support services.
Myeloma UK has called for patients, family members and carers to be more involved in developing guidance published by the National Institute for Health and Care Excellence (NICE). NICE, the drug approval body for England and Wales, had asked for views on proposals to improve how patients and the public can contribute to developing guidance on new treatments and care standards. A response submitted by Myeloma UK acknowledged the work NICE does to involve patients and the public but highlighted important areas where there is more to be done.
As a representative of the Scottish Cancer Coalition, Myeloma UK is participating in the Cancer Medicines Outcome Programme (CMOP) in Scotland with Dr Jayne Galinksy, Myeloma UK Health Services Research Manager, joining its Programme Board. CMOP is a 3 year Scottish Government funded programme, led by NHS Greater Glasgow and Clyde in collaboration with the University of Strathclyde, designed to determine the clinical effectiveness of cancer medicines in a real-life setting.